A Phase 3 interventional study of Sham injection and Ranibizumab 0.5 mg in Central Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 34 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 9th largest by enrollment, is one of 7 that started in 2013, is one of 13 in phase 3, and was the 31st registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 14 · Phase 4 13
First in 2006; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 47 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
20 studies in Retinal Vein Occlusion by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 14 (70%) have results posted.
Among the 20 studies in Retinal Vein Occlusion by Novartis, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 11 in phase 3, and was the 9th registered.
Novartis’s Retinal Vein Occlusion studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 20 in Retinal Vein Occlusion:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or nursing women or women of child bearing potential unless using an effective
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRN intravitreal injection
Drug: Ranibizumab 0.5 mg
As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
Other: Sham injection
Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
Also known as: Lucentis
Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 3 and compared to Baseline.
Time frame: Baseline, 3 Months
Average Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 12
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
Time frame: Baseline, 12 months
Best Corrected Visual Acuity (BCVA) Change From Baseline Over Time
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline
Time frame: Month 1 to 12 months
Change From Baseline in Central-Sub-Field- Thickness (CSFT) Over Time
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center.
Time frame: Month 1 to month 12
Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
Time frame: Month 1 to month 12
Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of <15 Letters in the Study Eye Over Time
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
Time frame: Month 1 to 12 months
The Change in Patient Reported Outcomes in NEI-VFQ-25 Score (Composite Score and Subscales) at Month 3, 6 and 12 Compared to Baseline
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
Time frame: Month 3,6 and 12
A total of 253 patients were randomized to this study, 191 patients to the ranibizumab group and 62 patients to the sham group. One patient randomized to the ranibizumab group was excluded from all analyses as informed consent was obtained after first study procedures were performed. Therefore, this patient not included in randomized set.
| Milestone | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Started | 190 | 62 |
| Completed 3 months | 186 | 60 |
| Discontinued study prior to 3 months | 4 | 2 |
| Completed | 173 | 53 |
| Not completed | 17 | 9 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Adverse event | 6 | 6 |
| Withdrew: Protocol violation | 2 | 0 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 3 and compared to Baseline.
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3 | 11.3 ± 10.77 | -2.7 ± 13.92 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Average Change of Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 12 | 12.4 ± 11.43 | 3.2 ± 14.62 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 | 9.6 ± 10.2 | -0.9 ± 12.17 |
| Month 2 | 11.6 ± 12.39 | -3.4 ± 16.04 |
| Month 3 | 12.6 ± 12.01 | -3.8 ± 17.02 |
| Month 4 | 10.7 ± 12.56 | 2.8 ± 15.26 |
| Month 5 | 11.7 ± 12.62 | 3.9 ± 15.26 |
| Month 6 | 12.3 ± 13.10 | 3.8 ± 17.20 |
| Month 7 | 12.9 ± 13.36 | 5.0 ± 16.71 |
| Month 8 | 12.4 ± 14.01 | 6.0 ± 16.01 |
| Month 9 | 13.1 ± 15.10 | 5.6 ± 16.95 |
| Month 10 | 13.5 ± 14.13 | 5.9 ± 16.77 |
| Month 11 | 14.2 ± 13.15 | 6.8 ± 16.30 |
| Month 12 | 14.5 ± 14.25 | 6.5 ± 17.10 |
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center.
| microns | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 | -393.7 ± 275.13 | -13.3 ± 207.55 |
| Month 2 | -412.6 ± 297.50 | -7.9 ± 196.65 |
| Month 3 | -433.3 ± 290.84 | -84.4 ± 274.98 |
| Month 4 | -367.8 ± 305.26 | -364.8 ± 250.48 |
| Month 5 | -407.0 ± 309.58 | -369.6 ± 273.92 |
| Month 6 | -426.6 ± 294.63 | -372.3 ± 301.24 |
| Month 7 | -421.5 ± 316.14 | -392.7 ± 288.74 |
| Month 8 | -398.9 ± 299.67 | -405.2 ± 289.49 |
| Month 9 | -422.1 ± 311.57 | -393.5 ± 323.50 |
| Month 10 | -431.7 ± 300.95 | -395.2 ± 309.67 |
| Month 11 | -438.1 ± 295.53 | -417.4 ± 288.08 |
| Month 12 | -441.7 ± 306.53 | -416.4 ± 294.08 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
| Participants | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 Gain of >=5 letters | 141 | 17 |
| Month 1 Gain of >=10 letters | 94 | 6 |
| Month 1 Gain of >=15 letters | 56 | 2 |
| Month 1 Gain of >=30 letters | 3 | 0 |
| Month 2 Gain of >=5 letters | 150 | 18 |
| Month 2 Gain of >=10 letters | 119 | 11 |
| Month 2 Gain of >=15 letters | 74 | 3 |
| Month 2 Gain of >=30 letters | 9 | 0 |
| Month 3 Gain of >=5 letters | 153 | 19 |
| Month 3 Gain of >=10 letters | 117 | 11 |
| Month 3 Gain of >=15 letters | 76 | 4 |
| Month 3 Gain of >=30 letters | 12 | 0 |
| Month 4 Gain of >=5 letters | 138 | 31 |
| Month 4 Gain of >=10 letters | 107 | 21 |
| Month 4 Gain of >=15 letters | 68 | 11 |
| Month 4 Gain of >=30 letters | 14 | 2 |
| Month 5 Gain of >=5 letters | 143 | 34 |
| Month 5 Gain of >=10 letters | 116 | 23 |
| Month 5 Gain of >=15 letters | 80 | 13 |
| Month 5 Gain of >=30 letters | 13 | 1 |
| Month 6 Gain of >=5 letters | 147 | 39 |
| Month 6 Gain of >=10 letters | 121 | 28 |
| Month 6 Gain of >=15 letters | 87 | 12 |
| Month 6 Gain of >=30 letters | 14 | 13 |
| Month 7 Gain of >=5 letters | 152 | 37 |
| Month 7 Gain of >=10 letters | 121 | 29 |
| Month 7 Gain of >=15 letters | 91 | 14 |
| Month 7 Gain of >=30 letters | 14 | 3 |
| Month 8 Gain of >=5 letters | 143 | 39 |
| Month 8 Gain of >=10 letters | 127 | 28 |
| Month 8 Gain of >=15 letters | 95 | 19 |
| Month 8 Gain of >=30 letters | 16 | 3 |
| Month 9 Gain of >=5 letters | 147 | 40 |
| Month 9 Gain of >=10 letters | 126 | 26 |
| Month 9 Gain of >=15 letters | 94 | 17 |
| Month 9 Gain of >=30 letters | 17 | 3 |
| Month 10 Gain of >=5 letters | 152 | 39 |
| Month 10 Gain of >=10 letters | 128 | 29 |
| Month 10 Gain of >=15 letters | 95 | 16 |
| Month 10 Gain of >=30 letters | 18 | 4 |
| Month 11 Gain of >=5 letters | 153 | 40 |
| Month 11 Gain of >=10 letters | 134 | 29 |
| Month 11 Gain of >=15 letters | 101 | 19 |
| Month 11 Gain of >=30 letters | 18 | 4 |
| Month 12 Gain of >=5 letters | 151 | 39 |
| Month 12 Gain of >=10 letters | 131 | 30 |
| Month 12 Gain of >=15 letters | 99 | 21 |
| Month 12 Gain of >=30 letters | 24 | 3 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
| Participants | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1, Loss of < 15 letters | 185 | 57 |
| Month 2, Loss of < 15 letters | 182 | 53 |
| Month 3, Loss of < 15 letters | 182 | 51 |
| Month 4, Loss of < 15 letters | 179 | 55 |
| Month 5, Loss of < 15 letters | 182 | 56 |
| Month 6, Loss of < 15 letters | 180 | 53 |
| Month 7, Loss of < 15 letters | 181 | 55 |
| Month 8, Loss of < 15 letters | 177 | 55 |
| Month 9, Loss of < 15 letters | 177 | 56 |
| Month 10, Loss of < 15 letters | 180 | 56 |
| Month 11, Loss of < 15 letters | 183 | 56 |
| Month 12, Loss of < 15 letters | 182 | 55 |
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
| Scores on a scale | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 3 | 4.4 ± 12.54 | 0.1 ± 13.78 |
| Month 6 | 6.7 ± 15.02 | 2.9 ± 13.33 |
| Month 12 | 8.2 ± 13.70 | 3.2 ± 15.34 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | — | 11/190 (5.8%) | 96/190 (50.5%) |
| Sham With Ranibizumab 0.5 mg | — | 5/56 (8.9%) | 32/56 (57.1%) |
| Sham Without Ranibizumab 0.5 mg | — | 1/5 (20%) | 3/5 (60%) |
| Event | Ranibizumab 0.5 mg | Sham With Ranibizumab 0.5 mg | Sham Without Ranibizumab 0.5 mg |
|---|---|---|---|
| Macular fibrosisEye disorders | 0/190 | 0/56 | 1/5 |
| Acute myocardial infarctionCardiac disorders | 0/190 | 1/56 | 0/5 |
| Left ventricular dysfunctionCardiac disorders | 0/190 | 1/56 | 0/5 |
| Angle closure glaucomaEye disorders | 2/190 | 1/56 | 0/5 |
| Wrist fractureInjury, poisoning and procedural complications | 0/190 | 1/56 | 0/5 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/190 | 1/56 | 0/5 |
| SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/190 | 1/56 | 0/5 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 0/190 | 1/56 | 0/5 |
| KeratitisEye disorders | 1/190 | 0/56 | 0/5 |
| Gastric ulcerGastrointestinal disorders | 1/190 | 0/56 | 0/5 |
| Event | Ranibizumab 0.5 mg | Sham With Ranibizumab 0.5 mg | Sham Without Ranibizumab 0.5 mg |
|---|---|---|---|
| AsthenopiaEye disorders | 2/190 | 0/56 | 1/5 |
| Dry eyeEye disorders | 7/190 | 1/56 | 1/5 |
| Eye painEye disorders | 4/190 | 2/56 | 1/5 |
| GlaucomaEye disorders | 2/190 | 0/56 | 1/5 |
| Iris neovascularisationEye disorders | 0/190 | 2/56 | 1/5 |
| Visual acuity reducedEye disorders | 9/190 | 3/56 | 1/5 |
| Vitreous detachmentEye disorders | 1/190 | 0/56 | 1/5 |
| DacryocystitisInfections and infestations | 0/190 | 0/56 | 1/5 |
| ParaesthesiaNervous system disorders | 0/190 | 0/56 | 1/5 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/190 | 2/56 | 1/5 |
| Age, Continuous(Years) | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|
| Mean | 54.1 ± 12.64 | 54.1 ± 13.29 | 54.1 ± 12.77 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|
| Female | 88 | 29 | 117 |
| Male | 102 | 33 | 135 |
Ran from Nov 2013 to primary completion in Mar 2016, 28 months.
Results were first posted in Apr 2017, 1 year 1 month after primary completion.
Of 18 phase 3 interventional studies under Retinal Vein Occlusion, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab